Advances in Pancreatic Cancer Immunotherapy
- 1st Edition - May 1, 2027
- Latest edition
- Editors: Vivek P. Chavda, Amit K. Tiwari, Zhe-Sheng Chen
- Language: English
Advances in Pancreatic Cancer Immunotherapy explores cutting-edge strategies to combat one of the most lethal malignancies. This book provides a focused, comprehensive resour… Read more
Description
Description
Key features
Key features
- Provides an in-depth analysis of immunotherapy mechanisms and their role in pancreatic cancer
- Highlights the latest innovations, including checkpoint inhibitors, cancer vaccines, and CAR T-cell therapies
- Examines clinical applications, challenges, and future directions for personalized treatment strategies
Readership
Readership
Table of contents
Table of contents
2. The Tumor Microenvironment in Pancreatic Cancer
3. Mechanisms of Immune Evasion in Pancreatic Cancer
4. Overview of Immunotherapy Approaches
5. Checkpoint Inhibitors in Pancreatic Cancer Treatment
6. Cancer Vaccines: Targeting Pancreatic Tumors
7. Adoptive Cell Transfer: CAR T-Cell Therapy
8. Combination Therapies: Enhancing Immunotherapy Efficacy
9. Personalized Immunotherapy Approaches
10. Challenges and Limitations of Immunotherapy in Pancreatic Cancer
11. Emerging Therapies and Future Directions
12. Regulatory Considerations and Biosimilars for Immunotherapy Products
13. Patient Perspectives and Quality of Life Considerations
Product details
Product details
- Edition: 1
- Latest edition
- Published: May 1, 2027
- Language: English
About the editors
About the editors
VC
Vivek P. Chavda
Vivek P. Chavda is an Assistant Professor (Selection Grade) in the Department of Pharmaceutics and Pharmaceutical Technology at L. M. College of Pharmacy, Ahmedabad, Gujarat, India. He earned Bachelor and Master of Pharmacy degrees and was a Gold Medallist at Gujarat Technological University. Before entering academia, he spent several years in the Biologics industry, contributing to R&D and regulatory filings for biologics. His scholarly output includes numerous peer‑reviewed articles, several books and book chapters, and ongoing writings in newsletters. His research spans the development of biologics processes and formulations, medical device development, nano diagnostics and noncarrier formulations, long-acting parenteral formulations, and nano vaccines. He also has patent assets in development and a record of industry-focused publications.
AT
Amit K. Tiwari
Dr. Amit K. Tiwari is a full Professor and Associate Dean of Research and Graduate Studies at UAMS. He completed graduate studies at St. John's University, NY, and pursued postdoctoral training in pharmacokinetics at Mount Sinai School of Medicine. A board-certified toxicologist and Diplomate of the American Board of Toxicology, he serves on multiple advisory boards and holds honorary professorships from Bundelkhand University and Bharati Vidyapeeth University. His work spans discovery, design, development, and delivery of targeted anticancer therapeutics addressing multidrug resistance. He has authored extensively in peer-reviewed journals, contributed book chapters, and presented at numerous conferences. He also reviews for many journals and chairs editorial duties, including as Associate Editor for Frontiers in Pharmacology and Frontiers in Oncology, while serving on additional editorial boards.
ZC